Because itolizumab acts upstream of pro-inflammatory cytokines, it may have greater potential than therapies targeting single cytokines to shut down runaway immune responses. In 2013, itolizumab ...
Scientists at the Institute for Systems Biology (ISB) have uncovered key insights into how T cells—the body's frontline ...
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback